多替阿巴拉米片治疗什么病？

It is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B*5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the RLA-B*5701 allele, he should not take products containing abacavir.

Trimax should not be used on individuals who carry the HLA-B*5701 gene. Patients who carry this gene are at high risk of developing severe hypersensitivity reactions (type I allergic reactions) when using Trimax. Therefore, before taking Suimeikai, you need to complete the test to determine whether you carry the special type of "HLA-B*5701" gene. Most hospitals can't do this test now, so doctors who prescribe Suimeikai will communicate the risks with infected people. Some companies that specialize in laboratory testing can do this test. You can contact the company to do it.

The most common symptoms of a hypersensitivity reaction are: fever (high fever) and rash. Other common reactions include: nausea (feeling like you are throwing up), vomiting, diarrhea, abdominal pain, and tiredness. May also include: joint or muscle pain, neck swelling, shortness of breath, sore throat, cough, occasional headache, eye inflammation (conjunctivitis), mouth sores, low blood pressure, and numbness in the hands and feet. Hypersensitivity reactions can occur at any time during treatment with Trimax, but are more common during the first 6 weeks of treatment.

You should pay attention to the usual use of (Suimeikai): The precautions for using Dote Abalamid Tablets (Suimeikai) are not clear yet. Patients should consult a physician or pharmacist in detail before taking medication and strictly follow the physician's recommendations.